<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Christian | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/routerjudo9/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/routerjudo9/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Christian.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">94a30d522232af0e713d6198d4600f94</guid>
				<title>Christian posted an update: The G-protein-coupled cannabinoid receptor type 2 (CB2R) is [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41124/</link>
				<pubDate>Fri, 07 Feb 2025 11:28:36 -0800</pubDate>

									<content:encoded><![CDATA[<p>The G-protein-coupled cannabinoid receptor type 2 (CB2R) is a key element of the endocannabinoid (EC) system. EC/CB2R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB2R agonism exerts anti-inflammatory and tissue protective&hellip;<span class="activity-read-more" id="activity-read-more-41124"><a href="http://www.nationalboardinstitute.com/activity/p/41124/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">49ecd708b378d13a95c48c246c6d8d0a</guid>
				<title>Christian posted an update: The guideline development and revision include an extensive [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34060/</link>
				<pubDate>Thu, 30 Jan 2025 11:42:21 -0800</pubDate>

									<content:encoded><![CDATA[<p>The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment&hellip;<span class="activity-read-more" id="activity-read-more-34060"><a href="http://www.nationalboardinstitute.com/activity/p/34060/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e0e39a263cc0c1be11855aa3f83af333</guid>
				<title>Christian posted an update: To date, several researchers have investigated the [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29511/</link>
				<pubDate>Tue, 28 Jan 2025 13:15:11 -0800</pubDate>

									<content:encoded><![CDATA[<p>To date, several researchers have investigated the association between dietary fibre consumption and satiety. However, there is no study that includes both inulin and β-glucan to compare energy intake (EI) and satiety ratings.</p>
<p> The current study investigated the effects of two dietary fibres, β-glucan and inulin, on satiety and food i&hellip;<span class="activity-read-more" id="activity-read-more-29511"><a href="http://www.nationalboardinstitute.com/activity/p/29511/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6f20db4a0d602b6d4cb70978f85aaf95</guid>
				<title>Christian became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29393/</link>
				<pubDate>Tue, 28 Jan 2025 13:07:35 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>